Advertisement
Screener

IMMUNITYBIO, INC. (IBRX) Operating Lease, Payments

2.8 / 5 stars · 68/120 Roast Me

IMMUNITYBIO, INC. Operating Lease, Payments

IMMUNITYBIO, INC. (IBRX) reported Operating Lease, Payments of $6.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Cash Flow › Other Cash Flow Items

us-gaap:OperatingLeasePayments · last filed 2026-08-04

  • IMMUNITYBIO, INC. operating lease, payments for the quarter ending 2026-06-30 was $3.13M, a 6.93% increase year-over-year.
  • IMMUNITYBIO, INC. operating lease, payments for the quarter ending 2026-03-31 was $3.18M, a 8.68% increase year-over-year.
  • IMMUNITYBIO, INC. operating lease, payments for the quarter ending 2025-12-31 was $2.91M, a 4.87% increase year-over-year.
  • IMMUNITYBIO, INC. operating lease, payments for the quarter ending 2025-09-30 was $2.91M, a 2.11% increase year-over-year.
  • IMMUNITYBIO, INC. operating lease, payments for fiscal 2025 was $11.67M, a 9.66% increase from fiscal 2024.
  • IMMUNITYBIO, INC. operating lease, payments for fiscal 2024 was $10.64M, a 11.57% increase from fiscal 2023.
  • IMMUNITYBIO, INC. operating lease, payments for fiscal 2023 was $9.54M, a 6.86% decline from fiscal 2022.
  • IMMUNITYBIO, INC. operating lease, payments for fiscal 2022 was $10.24M, a 13.36% increase from fiscal 2021.
Period endOperating Lease, Payments 3 monthOperating Lease, Payments 3 month as first filedOperating Lease, Payments 6 monthOperating Lease, Payments 6 month as first filedOperating Lease, Payments 9 monthOperating Lease, Payments 9 month as first filedOperating Lease, Payments 12 monthOperating Lease, Payments 12 month as first filed
2026-06-30$3.13M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$6.31M
10-Q · filed 2026-08-04
$9.22M
derived: sum of 3 quarters · filed 2026-08-04
$12.13M
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31$3.18M
10-Q · filed 2026-05-07
$6.09M
derived: sum of 2 quarters · filed 2026-05-07
$8.99M
derived: sum of 3 quarters · filed 2026-05-07
$11.92M
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31$2.91M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23
$5.82M
derived: sum of 2 quarters · filed 2026-02-23
$8.74M
derived: sum of 3 quarters · filed 2026-08-04
$11.67M
10-K · filed 2026-02-23
2025-09-30$2.91M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
$5.84M
derived: sum of 2 quarters · filed 2026-08-04
$8.76M
10-Q · filed 2025-11-05
$11.54M
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30$2.93M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$5.86M
10-Q · filed 2026-08-04
$8.63M
derived: sum of 3 quarters · filed 2026-08-04
$11.47M
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31$2.92M
10-Q · filed 2026-05-07
$5.70M
derived: sum of 2 quarters · filed 2026-05-07
$8.54M
derived: sum of 3 quarters · filed 2026-05-07
$11.18M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$2.77M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23
$5.62M
derived: sum of 2 quarters · filed 2026-02-23
$8.26M
derived: sum of 3 quarters · filed 2026-02-23
$10.64M
10-K · filed 2026-02-23
2024-09-30$2.85M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
$5.48M
derived: sum of 2 quarters · filed 2025-11-05
$7.87M
10-Q · filed 2025-11-05
$9.69M
derived: sum of 4 quarters · filed 2026-02-23
2024-06-30$2.64M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05
$5.02M
10-Q · filed 2025-08-05
$6.85M
derived: sum of 3 quarters · filed 2026-02-23
$8.72M
derived: sum of 4 quarters · filed 2026-02-23
2024-03-31$2.38M
10-Q · filed 2025-05-12
$4.21M
derived: sum of 2 quarters · filed 2026-02-23
$6.08M
derived: sum of 3 quarters · filed 2026-02-23
$8.74M
derived: sum of 4 quarters · filed 2026-02-23
2023-12-31$1.82M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23
$3.70M
derived: sum of 2 quarters · filed 2026-02-23
$6.36M
derived: sum of 3 quarters · filed 2026-02-23
$9.54M
10-K · filed 2026-02-23
2023-09-30$1.87M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
$4.53M
derived: sum of 2 quarters · filed 2024-11-12
$7.71M
10-Q · filed 2024-11-12
$10.60M
derived: sum of 4 quarters · filed 2025-03-03
2023-06-30$2.66M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12
$5.84M
10-Q · filed 2024-08-12
$8.73M
derived: sum of 3 quarters · filed 2025-03-03
$10.99M
derived: sum of 4 quarters · filed 2025-03-03
2023-03-31$3.18M
10-Q · filed 2024-05-09
$6.07M
derived: sum of 2 quarters · filed 2025-03-03
$8.33M
derived: sum of 3 quarters · filed 2025-03-03
$11.27M
derived: sum of 4 quarters · filed 2025-03-03
2022-12-31$2.89M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03
$5.15M
derived: sum of 2 quarters · filed 2025-03-03
$8.09M
derived: sum of 3 quarters · filed 2025-03-03
$10.24M
10-K · filed 2025-03-03
2022-09-30$2.26M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
$5.20M
derived: sum of 2 quarters · filed 2023-11-09
$7.35M
10-Q · filed 2023-11-09
$10.51M
derived: sum of 4 quarters · filed 2024-03-19
2022-06-30$2.94M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08
$5.09M
10-Q · filed 2023-08-08
$8.25M
derived: sum of 3 quarters · filed 2024-03-19
$10.12M
derived: sum of 4 quarters · filed 2024-03-19
2022-03-31$2.15M
10-Q · filed 2023-05-11
$5.31M
derived: sum of 2 quarters · filed 2024-03-19
$7.18M
derived: sum of 3 quarters · filed 2024-03-19
$9.51M
derived: sum of 4 quarters · filed 2024-03-19
2021-12-31$3.16M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19
$5.03M
derived: sum of 2 quarters · filed 2024-03-19
$7.36M
derived: sum of 3 quarters · filed 2024-03-19
$9.03M
10-K · filed 2024-03-19
2021-09-30$1.87M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
$4.20M
derived: sum of 2 quarters · filed 2022-11-09
$5.88M
10-Q · filed 2022-11-09
$9.50M
derived: sum of 4 quarters · filed 2022-11-09
2021-06-30$2.33M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08
$4.00M
10-Q · filed 2022-08-08
$7.63M
derived: sum of 3 quarters · filed 2022-08-08
$8.72M
derived: sum of 4 quarters · filed 2022-08-08
2021-03-31$1.68M
10-Q · filed 2022-05-10
$5.30M
derived: sum of 2 quarters · filed 2022-05-10
$6.40M
derived: sum of 3 quarters · filed 2022-05-10
$7.50M
derived: sum of 4 quarters · filed 2022-05-10
2020-12-31$3.62M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
$4.72M
derived: sum of 2 quarters · filed 2022-03-01
$5.82M
derived: sum of 3 quarters · filed 2022-03-01
$7.84M
10-K · filed 2022-03-01
$5.34M
10-K · filed 2021-03-04
2020-09-30$1.10M
10-Q · filed 2020-11-09
$2.20M
derived: sum of 2 quarters · filed 2020-11-09
$4.22M
10-Q · filed 2021-11-12
$3.20M
10-Q · filed 2020-11-09
$7.83M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30$1.10M
10-Q · filed 2020-08-07
$2.79M
10-Q · filed 2021-08-12
$2.10M
10-Q · filed 2020-08-07
$6.73M
derived: sum of 3 quarters · filed 2022-03-01
$7.73M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31$1.35M
10-Q · filed 2021-05-14
$1.00M
10-Q · filed 2020-05-11
$5.63M
derived: sum of 2 quarters · filed 2022-03-01
$6.63M
derived: sum of 3 quarters · filed 2022-03-01
$7.63M
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31$4.27M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
$5.27M
derived: sum of 2 quarters · filed 2022-03-01
$6.27M
derived: sum of 3 quarters · filed 2022-03-01
$7.57M
10-K · filed 2022-03-01
$4.40M
10-K · filed 2020-03-25
2019-09-30$1.00M
10-Q · filed 2020-11-09
$2.00M
derived: sum of 2 quarters · filed 2020-11-09
$3.30M
10-Q · filed 2020-11-09
2019-06-30$1.00M
10-Q · filed 2020-08-07
$2.30M
10-Q · filed 2020-08-07
2019-03-31$1.30M
10-Q · filed 2020-05-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
REPLIGEN CORP (RGEN)United States$10.755B185.31
Immunovant, Inc. (IMVT)United States$7.028B-14.78
BIO-TECHNE Corp (TECH)United States$11.379B74.68
Twist Bioscience Corp (TWST)United States$11.540B-47.21
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
CRISPR Therapeutics AG (CRSP)$5.390B-11.68